Alnylam Pharmaceuticals (ALNY)
Health Care · Biotechnology · NASDAQ
Alnylam is a pioneer in RNA interference (RNAi) therapeutics, using gene-silencing technology to treat rare genetic diseases and cardiovascular conditions.
What Alnylam Pharmaceuticals does
Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development, and commercialization of RNA interference (RNAi) therapeutics. The company utilizes proprietary platforms, including GalNAc-conjugate and lipid nanoparticle delivery technologies, to silence disease-causing genes by targeting messenger RNA (mRNA). Its commercial portfolio includes six first-in-class RNAi-based medicines treating conditions such as hereditary transthyretin-mediated amyloidosis, acute hepatic porphyria, and primary hyperoxaluria type 1.
Themes: RNA interference / RNAi therapeutics, gene silencing, rare disease therapeutics, cardiovascular medicine, precision medicine
Fundamentals
- Price$236.22 as of 2026-08-21 close
- Market cap$31.6B as of 2026-08-21
- 1-year return-49.5% 2025-08-21 close $467.55 → 2026-08-21 close $236.22
- P/E37.61 as of 2026-08-24
- Net margin+16.8% as of 2026-08-24
- Gross margin+79.7% as of 2026-08-24
- ROE+93.6% as of 2026-08-24
- Debt / equity2.02 as of 2026-08-24
- Revenue growth (YoY)+95.1% as of 2026-08-24
- Revenue CAGR (3y)+53.0% SEC XBRL
- Beta0.25 as of 2026-08-24
- Last reported earnings2026-07-30 SEC EDGAR Form 8-K (Item 2.02)
How ALNY compares in its sector
- price-to-earnings ratiomiddle range 203 covered Health Care peers, as of 2026-08-24
- net profit margintop 25% 504 covered Health Care peers, as of 2026-08-24
- operating margintop 25% 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitytop 10% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRtop 25% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)top 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
ALNY is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no shareholder return data.
Short-term score
25.6 #1682 of 1,704 scored · #236 of 240 in Health Care
Momentum 36th: MACD momentum is positive; volume and participation 32nd: trading volume is about normal versus its 30-day average; weakest is setup 8th: no fresh 20-day breakout up or down.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How Alnylam Pharmaceuticals looks technically
Alnylam Pharmaceuticals (ALNY) is trading 29.1% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 130 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 19, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 47, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 6 trading days ago (its momentum flipped positive). It made a new 20-day low about 17 trading days ago. It is 52.3% below its highest point of the past year.
Trend
7
| Distance from the 200-day | it is trading 29.1% below its 200-day average, the long-term trend line — a long-term downtrend | -29.1% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $266.73 | $266.73 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $333.34 | $333.34 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 15 calendar days ago — the swings before that are what the structure reading is measured on | 15 sessions |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 130 trading days ago — a "death cross", a bearish long-term signal | 130 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 19, below the 25 that marks a real trend) | 19.0 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 47, neither overbought (above 70) nor oversold (below 30) | 46.6 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($210.49 to $244.00) — its "stochastic" reading is 77 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 76.8 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 6 trading days ago (its momentum flipped positive) | 6 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $495.55 | $495.55 |
|---|---|---|
| From the 52-week high | it is 52.3% below its 52-week high (its highest price of the past year) | -52.3% |
| Above the 52-week low | it is 19.4% above its 52-week low (its lowest price of the past year) | +19.4% |
| Below the 52-week high | it is 52.3% below its highest point of the past year | 52.3% |
| Since a 20-day breakout | it made a new 20-day low about 17 trading days ago | 17 sessions |
| Since a 55-day breakout | it made a new 55-day low about 17 trading days ago | 17 sessions |
| All-time high | its highest closing price on record is $495.55 (set on 2025-10-20) | $495.55 |
| Given back of the 52-week move | over the past year its closes ranged ($205.48 to $491.22), and it has recovered only a small part of its fall from last year’s high — 11% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $382.07 to $391.21. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 10.8% |
| From the all-time high | it is 52.3% below its all-time high | -52.3% |
| Nearest price level | it is trading 1.9% above a support level at $231.81 — a price it turned at five times since 2024-11-18, most recently on 2026-08-06. Since 2024-08-21 it has 1 such level below the current price and 13 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -1.9% |
| All-time low | its lowest closing price on record is $5.88 (set on 2011-10-04) | $5.88 |
| Above the all-time low | it is 3918.0% above its all-time low | +3,918% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually wide versus its own recent history (wider than about 87% of the past ~6 months) | 87th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $12.45 between its high and its low — about 5.3% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $12.45 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $185.24 and $279.47 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $185.24 – $232.35 – $279.47 |
| Typical daily range (% of price) | its price moves about 5.3% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 5.3% |
| Stretch from the 200-day average | it is trading 7.8 daily ranges below its 200-day average price (29.1% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 7.8 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.93× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 0.9% since the prior reading | -0.9% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.2% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.2% |
|---|---|---|
| Open gap | it gapped 21.5% below the previous close 16 sessions ago and has not traded back through the level it left behind at 286.62 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -21.5% |
| Gap filled | a 2.5% gap up opened on 2026-08-19 has been "filled" today — price traded back through the level the gap left behind, and it took 2 sessions to close | today |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 15.3 percentage points (the stock lost 13.0% while the market gained 2.3%) | -15.3% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 24.5 percentage points (the stock lost 21.4% while the market gained 3.1%) | -24.5% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 40.8 percentage points (the stock lost 29.7% while the market gained 11.1%) | -40.8% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 70.0 percentage points (the stock lost 49.5% while the market gained 20.5%) | -70.0% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: MACD momentum is positive — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 4 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 4 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 28% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thin, spanning 0.1% of the share price, which is taken to mean a barrier that gives way easily. | -27.7% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 21% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $298.95 — a volume-weighted average of daily closes over 157 sessions, not a true tick-by-tick VWAP. | -21.0% |
|---|---|---|
| Vs the average paid since it last reported | the price is 8% above the average price paid since it last reported on 2026-07-30 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $218.66 — a volume-weighted average of daily closes over 17 sessions, not a true tick-by-tick VWAP. | +8.0% |
Price levels it has turned at before
ALNY last closed at $236.22 on 2026-08-21. Since 2024-08-21 it has turned at 1 price below its last close and 13 above; the nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $231.81 | Support | 1.9% below the last close | turned there five times · 2024-11-18 to 2026-08-06 |
| $245.44 | Resistance | 3.9% above the last close | turned there twice · 2024-09-06 to 2025-05-08 |
| $265.29 | Resistance | 12.3% above the last close | turned there four times · 2024-09-24 to 2025-02-03 |
| $278.85 | Resistance | 18.1% above the last close | turned there twice · 2024-09-19 to 2025-05-07 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · trendless / choppy (low ADX) · lagging the market · Stretched far below its 200-day average (6+ daily ranges) · Trading below the Ichimoku cloud | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingBuy (1.68 mean, 1=Strong Buy…5=Strong Sell) — 26 analysts
- Mean price target$370.20 range $230.00 – $536.00; median $350.00
Analyst estimates, as of 2026-08-24. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for ALNY
- Consensus EPS estimate$2.32 next reporting period, as of 2026-08-24
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Dependence on successful regulatory approval and commercial uptake of the RNAi therapeutic pipeline.","Risks associated with reliance on collaborations and partnerships for product development and commercialization.","Significant competition from traditional pharmaceutical companies and other biotechnology firms."]
What changed in the latest 10-Q
AI-assisted comparison of ALNY's 10-Q filed 2026-04-30 against the prior one filed 2025-10-30.
Management's Discussion & Analysis (MD&A)
- Added:
- In early 2026, we launched our Alnylam 2030 strategy to drive the Company's next era of growth and patient impact (newer filing 2026-04-30)
- More than 25 clinical programs mentioned (newer filing 2026-04-30), compared to more than 20 in older filing
- Two products commercialized by collaborators explicitly noted (newer filing 2026-04-30)
- Health Canada approval for AMVUTTRA for ATTR amyloidosis with cardiomyopathy added (newer filing 2026-04-30)
- Nucresiran development details added including Phase 1 results from November 2024 showing >90% serum TTR reductions and twice annual 300 mg dosing (newer filing 2026-04-30)
- TRITON-PN Phase 3 clinical trial of nucresiran initiated in September 2025 (newer filing 2026-04-30)
- TRITON-CM Phase 3 clinical trial initiated in June 2025 (newer filing 2026-04-30)
- Qfitlia approval by China's NMPA in December 2025 added (newer filing 2026-04-30)
- Removed:
- Alnylam P 5 x25 strategy description removed (was in older filing 2025-10-30)
- Reference to 'transition to a top-tier biotech company by the end of 2025' removed (older filing 2025-10-30)
- Colombian Health Authority approval for AMVUTTRA removed and replaced with Health Canada (older filing 2025-10-30 mentioned Colombia, newer filing 2026-04-30 mentions Health Canada)
- References to pending or planned regulatory filings 'during 2025 and beyond' changed to '2026 and beyond' for GIVLAARI and OXLUMO
- Zilebesiran development details and Roche collaboration details removed from the excerpt
- Reworded:
- Changed 'we have developed a new class' to 'we have pioneered a new class' regarding RNAi therapeutics (newer filing 2026-04-30)
- Qfitlia trademark changed from '™' to '®' (newer filing 2026-04-30)
- AMVUTTRA cardiomyopathy approval details reorganized: moved Brazilian, Japanese, UK, and Canadian approvals after EC approval paragraph in newer filing
- Leqvio indication description simplified in newer filing: removed 'as an adjunct to diet and maximally tolerated statin therapy' language and specific ASCVD/HeFH descriptions from older filing
- Changed 'Leqvio (inclisiran), our fifth product' to 'Leqvio (inclisiran)' removing ordinal reference (newer filing 2026-04-30)
- Changed 'Qfitlia (fitusiran), our sixth product' to 'Qfitlia (fitusiran)' removing ordinal reference (newer filing 2026-04-30)
- Leqvio country registration update: from '107 countries' and '87 countries' (as of end of September 2025) to 'more than 108 countries' and '89 countries' (as of end of March 2026) (newer filing 2026-04-30)
- Notes:
- The newer filing text appears truncated at the end of the nucresiran paragraph, limiting full comparison of later sections
- The older filing excerpt also appears truncated, cutting off mid-sentence in the Leqvio description and Roche collaboration discussion
Risk Factors
- Added:
- Added new bullet point under Business Related Risks – Risks Related to Our Financial Results: 'If we are unable to sustain and grow revenues from sales of AMVUTTRA, our business would be materially harmed, our future operating results would be adversely impacted, and the market price of our common stock would likely decline.' (filed 2026-04-30)
- Added phrase 'us with external innovation or' in collaboration risk bullet point (filed 2026-04-30)
- Added new bullet point under Risks Related to Managing Our Operations: 'We may have difficulty continuing to expand our global operations successfully.' (filed 2026-04-30)
- Removed:
- Removed the specific descriptive clause about company evolution in the operations risk: 'as we continue our evolution from a U.S.- and Europe-based company primarily involved in discovery, preclinical testing and clinical development into a global company that develops and commercializes multiple drugs in multiple geographies' (filed 2025-10-30)
- Removed phrase 'and remain' from profitability risk bullet point (filed 2025-10-30)
- Reworded:
- Changed 'We have a history of losses and may not become and remain profitable' to 'We have a history of losses and may not sustain profitability' (filed 2026-04-30)
- Changed 'with other companies that can provide business and scientific capabilities' to 'with other companies that can provide us with external innovation or with business and scientific capabilities' (filed 2026-04-30)
- Changed 'result in significant negative consequences following any potential marketing approval' to 'result in significant negative consequences following any potential regulatory approval' (filed 2026-04-30)
- Changed 'We may have difficulty expanding our operations successfully as we continue our evolution from a U.S.- and Europe-based company...' to 'We may have difficulty continuing to expand our global operations successfully' (filed 2026-04-30)
- Notes:
- The newer filing text appears truncated at the end of the Competition section, limiting full comparison of that section
- The older filing text is also truncated at the end, preventing complete comparison of the final risk factor
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 5 open-market sales by insiders in the last 90 days.
- Last 90 days0 buys · 5 sells ($1M) — 1 selling insider
- Last 180 days0 buys · 19 sells ($2M) — 2 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-06-01. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about ALNY's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 1 matched disclosure for ALNY from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Institutional ownership (13F)
5 institutional 13F filers reported holding ALNY as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 28,564,579
- Reported value $9,451,162,292
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 3 increased, 2 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
ALNY had 4,803,194 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
ALNY had 3.59% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 2.18 days to cover at the same settlement.
- Reported short interest (shares) 4,803,194
- Short interest (% of shares outstanding) 3.59%
- Prior settlement (shares) 5,773,373
- Reported change -16.8%
- Days to cover (reported) 2.18
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Ionis Pharmaceuticals (IONS)
- Arrowhead Pharmaceuticals (ARWR)
- BridgeBio Pharma (BBIO)
- Pfizer (PFE)
- Novartis (NVS)
- AstraZeneca (AZN)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ALNY vs…
Alnylam Pharmaceuticals is found in…
ALNY ranks in…
Frequently asked questions
What does Alnylam Pharmaceuticals (ALNY) do?
Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development, and commercialization of RNA interference (RNAi) therapeutics. The company utilizes proprietary platforms, including GalNAc-conjugate and lipid nanoparticle delivery technologies, to silence disease-causing genes by targeting messenger RNA (mRNA).
What sector is Alnylam Pharmaceuticals (ALNY) in?
Alnylam Pharmaceuticals (ALNY) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are Alnylam Pharmaceuticals's (ALNY) competitors?
Notable peers of Alnylam Pharmaceuticals (ALNY) include Ionis Pharmaceuticals, Arrowhead Pharmaceuticals, BridgeBio Pharma, Pfizer and Novartis. This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in ALNY?
Yes — we hold 1 matched STOCK Act disclosure for ALNY from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is Alnylam Pharmaceuticals (ALNY) overbought or oversold right now?
Alnylam Pharmaceuticals (ALNY) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 47, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ALNY come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.